Cormedix (HAM:19KA) Net Interest Margin (Bank Only) %


HAM:19KA Cormedix Inc HAM:19KA
39 GF Score
Price €6.71
GF Value €56.66
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

HAM:19KA
39GF Score
Cormedix Inc HAM:19KA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €6.71 is trading 88.2% below its estimated GF Value™ of €56.66. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €56.66 vs. price of €6.71 (88.2% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
39GF Score

Get the complete analysis for HAM:19KA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.71
Price
€56.66
GF Value